Anatomy and Neuroscience - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/181

Filters

2021 2
2
Reset filters

Settings
Statistics
Citations
Author: Monif, Mastura × Author: van der Walt, Anneke × End date: 2021 × Start date: 2020 ×

Search Results

Now showing 1 - 2 of 2
  • Item
    No Preview Available
    Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders.
    Rath, L ; Campagna, MP ; Stankovich, J ; Ellis, J ; Jokubaitis, V ; McCarthy, D ; Nesbitt, C ; Yeh, WZ ; Zhong, M ; Wesselingh, R ; Monif, M ; Richards, J ; Minh, VB ; Skibina, O ; Butzkueven, H ; van der Walt, A (Consortium of Multiple Sclerosis Centers, 2021)
    BACKGROUND: People with multiple sclerosis and neuroimmunologic disorders (herein referred to as patients) are increasingly treated with infusible monoclonal antibodies. This rise in demand has placed increased loads on current infusion services and mandates careful strategic planning. This study examined patient preferences for the timing and location of infusions and their association with demographic and disease variables to facilitate patient-focused strategic planning. METHODS: Ninety-one patients receiving an infusible therapy at an infusion service during March 2019 were asked to complete a questionnaire exploring eight domains, including preferences for time of infusions and location of infusion centers. Potential access to home-based treatment was included as an option. Unstructured (free-text) feedback on current service was also obtained. RESULTS: Eighty-three patients completed the survey (mean age, 42 years; 75% women). Infusions were predominantly natalizumab (66%) and ocrelizumab (25%). Of these patients, 71% were engaged in some form of work or study, and 83% of this group had to arrange time off from work or study to attend treatment. Seventy percent of patients would prefer their infusion before noon, and 60% would consider home-based infusions. Most used a car as their transport to the infusion service. CONCLUSIONS: These results suggest that patients are more likely to prefer infusible treatment in the morning and are open to home-based infusions. This study provides information for health services to target service delivery at peak preference times and consider alternate ways of delivering infusible treatments.
  • Item
    No Preview Available
    Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic
    Rath, L ; Bui, MV ; Ellis, J ; Carey, J ; Baker, J ; Taylor, L ; Fernando, H ; Taylor, N ; Savage, P ; Richards, J ; Zhong, M ; Kalincik, T ; Skibina, O ; Wesselingh, R ; Nguyen, A-L ; Monif, M ; Butzkueven, H ; van der Walt, A (ELSEVIER SCI LTD, 2021-01)
    BACKGROUND: The COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time in clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients. OBJECTIVE: To analyse the rate of infusion related reactions and patient experience of rapid infusions of natalizumab and ocrelizumab. To document time reduction patients spent in clinical settings during the COVID-19 pandemic. METHODS: Patients with prior exposure to at least three natalizumab or two 300mg ocrelizumab infusions were approved for rapid protocols. A retrospective audit and survey were completed. RESULTS: We analysed 269 rapid natalizumab infusions and 100 rapid ocrelizumab infusions. Infusion related reactions during the natalizumab or ocrelizumab infusions occurred in two patients (1.52%) and eight patients (8%), respectively. All infusion related reactions were mild to moderate and did not require infusion discontinuation. No infusion reactions occurred during the post-infusion observation. Patient experience was positive. CONCLUSION: Frequency or severity of infusion related reactions in rapid infusions were no different compared to published data. In the setting of COVID-19, pandemic rapid infusion protocols could potentially save hospital resources and limit patient exposure to a high-risk clinical setting while still maintaining ongoing treatment of multiple sclerosis.